Introduction
The occurrence of hypercalcaemia secondary to malignant lymphoma has been described previously (Herrmann, Kirsten and Krakauer, 1949; Plimpton and Gellhorn, 1956; Kabakow, Mines and King, 1957 ; Moses and Spencer, 1963; Powell et al., 1973; Singer et al., 1973; Canellos, 1974) although the incidence of this complication (less than 2%/ of cases of advanced lymphoma have elevated serum calcium levels at presentation [Canellos, 1974] ) is lower than might be predicted from the relative frequency of bone marrow involvement in this condition.
The majority of cases described in the literature had bone involvement by lymphomatous tissue and all patients had disseminated disease.
The authors have recently seen 3 patients with disseminated malignant lymphoma who developed hypercalcaemia. One was found to have raised serum calcium level at the time of presentation; the other 2 developed the abnormality during the course of their disease. In 2 cases the hypercalcaemia may have been a major factor in the death of the patient. mg/day and the patient allowed home. Two days later the patient was re-admitted in a semi-comatose state with a history of rapid mental deterioration, vomiting and urinary incontinence. She was again dehydrated and had developed bronchopneumonia. The serum calcium level was now markedly elevated at 5 0 mmol/l with blood urea of 10 7 mmol/l and there was severe hypokalaemic alkalosis. Resuscitative measures, including intravenous fluids, hydrocortisone, phosphate infusion and broad spectrum antibiotics were unsuccessful and the patient died 24hr after admission. Post-mortem was not performed.
Case 2
A 49-year-old male presented with autoimmune haemolytic anaemia thought to be associated with chronic lymphocytic leukaemia. He responded to prednisolone but 7 months later he required admission to hospital with acute renal failure. At this time his serum calcium, phosphate, alkaline phosphatase and uric acid levels were all normal (2-27, 1-1 mmol/l, 64 u./l, 0 43 mmol/l respectively). He was treated with peritoneal dialysis and made a good recovery from his renal failure. Renal biopsy, however, showed infiltration by malignant lymphoma. Diagnostic laparatomy one month later revealed infiltration of the liver with nonHodgkin's lymphoma of a large cleaved follicular centre cell type, with normal spleen histology. He was treated initially with chlorambucil but developed weight loss and the chest radiograph revealed changes consistent with pulmonary involvement from lymphoma. Bone marrow trephine also demonstrated involvement by malignant lymphoma although skeletal radiographs were normal. Haemoglobin at this stage was 11-3 g/dl, white cell count 12 0 x 109/1 with 7 0 x 109/l lymphocytes many of which were of abnormal morphology. The platelet count was 250 x 109/l and ESR 26 mm/hr (Westergren). At this time the patient was dehydrated and feverish and the serum biochemical screen revealed elevated levels of urea, uric acid and calcium (10 0, 0-53, 3 59 mmol/l respectively). Oral fluids were increased and treatment with COPAd regime begun, together with allopurinol. The serum calcium level had fallen to 3-16 mmol/l at 48 hours and 2-48 mmol/l by 7 days. The blood urea rose to 30 0 mmol/l before falling to 9 3 mmol/l by 7 days. Clinical improvement was dramatic and marked regression of the pulmonary deposits was noted. The patient has since completed 6 courses of combination chemotherapy and appears to be in complete remission. His serum biochemical screen remains normal and the serum calcium level in particular is 2-22 mmol/l. In Case 2 hypercalcaemia developed insidiously with associated widespread disease. In this case response to oral hydration and cytotoxic chemotherapy (including prednisolone) was less rapid, although the serum calcium level had fallen significantly by 48 hr. The serum calcium has continued at a normal level whilst the non-Hodgkin's lymphoma has been in remission.
The third case showed hypercalcaemia at the time of presentation with advanced malignant lymphoma and his biochemical abnormalities may well have contributed to his rapid deterioration; there was no clinical or biochemical improvement in this case with cytotoxic chemotherapy (incorporating prednisolone).
None of the patients showed radiological evidence of bone involvement, although bone marrow trephine biopsy was positive for lymphoma in 2 cases (Cases 1 and 2). Indeed, bone marrow infiltration or osteolytic bone lesions occur in about 50%4 of cases of advanced lymphoma (Canellos, 1974; Richmond et al., 1962) (Tashjian, Levine and Munson, 1964; Munson, Tashjian and Levine, 1965; Sherwood et al., 1967; Omenn, Roth and Baker, 1969) although adequate parathyroid hormone and radio-immunoassay data have rarely been obtained. It now seems likely that in the majority of cases parathyroid hormone-like activity produced ectopically by the tumour is not the underlying mechanism of the hypercalcaemia (Powell et al., 1972) , and other mechanisms have been postulated.
The direct resorption of bone by tumour tissue remains a possibility but this fails to explain the low incidence of hypercalcaemia in haematological malignancies other than myelomatosis in which bone marrow involvement may be very extensive; even in this condition, however, bone resorption appears to be mediated by increased numbers of osteoclasts, rather than by the abnormal plasma cells (Mundy et al., 1974b) .
There is some in vitro evidence that normal human monocytes can resorb bone by a humoral mechanism (Munday et al., 1977) , but the importance of this in vivo is not known.
Various humoral agents have been postulated as mediators of hypercalcaemia in malignant and inflammatory disease. In some carcinomas, particularly those of breast (Greaves et al., 1976; Powles et al., 1976; Dowsett et al., 1976; Bennett et al., 1976; Bennett et al., 1977) and kidney Greaves, Atkins and Martin, 1977) , large amounts of prostaglandins have been demonstrated and some of these tumours can resorb bone in vitro by a mechanism that seems to involve the production of bone-resorbing prostaglandins (particularly prostaglandin E) and the stimulation of osteoclasts. Prostaglandin production has been shown to be important in the genesis of hypercalcaemia in some animal tumours (Tashjian et al., 1972; Powles et al., 1973; Woelkel et al., 1975; Seyberth et al., 1976; Seyberth et al., 1977) . There is, however, no evidence that the bone-resorbing agent liberated by lymphoid cell lines in culture is a prostaglandin (Mundy et al., 1974a) or indeed that cultured bone marrow cells from patients with myeloma can elaborate prostaglandins in significant amounts, although they can produce immunoglobulin (Mundy et al., 1974b; Greaves, 1977, unpublished observations) .
The production of vitamin D-like sterols by tumours has been postulated (Gordan, Cantino and Erhardt, 1966) , although there is little evidence to support this.
The humoral agent which seems most likely to be of importance in myeloma and lymphoreticular malignancy is the so-called osteoclast activating factor (OAF) which has been shown to be produced by myeloma cells (Mundy et al., 1974b ). This appears to be indistinguishable from the boneresorbing factor produced by phytohaemagglutininstimulated human leucocytes in culture (Horton et al., 1972; Luben et al., 1974) . It has been demonstrated that the in vitro bone resorption induced by this macromolecular compound is inhibited by low concentrations of cortisol (Horton et al., 1972) and it is possible that this may be the mechanism for the response of the hypercalcaemia to prednisolone that was seen in 2 of the patients (Cases 1 and 2).
The inhibition of production of a humoral agent by the malignant cells, rather than interference with the action of such an agent on bone, by corticosteroids remains a possible explanation for the activity of these drugs in hypercalcaemia, although there is no experimental evidence to support this.
This applies particularly to Case 1 where the response was dramatic and rapid; in Case 2 the slower response of the hypercalcaemia may also reflect the reduction in tumour mass by the cytotoxic chemotherapy (including prednisolone).
The authors feel that hypercalcaemia in malignant lymphoma, although uncommon, may be important particularly as the resulting clinical state may be mistaken for that of the underlying malignant process in patients with advanced disease.
In one of the patients, the initial response to hydration, oral phosphate and high doses of prednisolone was extremely rapid and in a second patient there was a slower but sustained response to cytotoxic chemotherapy. This indicates that the potentially lethal condition of hypercalcaemia in cases of malignant lymphoma may respond (together with the underlying disease) to appropriate chemotherapy. It is therefore worth-while checking the serum calcium level regularly in such patients so that any abnormality can be treated early and energetically. 
